Recent advances in the treatment of polycystic ovary syndrome

Bibliography

• KNOCHENHAUER ES, KEY TJ, KAHSAR-MILLER M et al.:Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. Clin. Endocrine] Metab.(1998) 83(9):3078–3082.
   PubMed Web of Science ®Google Scholar
• DIAMANTI-KANDARAKIS E, KOULI CR, BERGIELE AT et al.:A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. Clin. Endocrine] Metab.(1999) 84(11):4006–4011.
   PubMed Web of Science ®Google Scholar
• ASUNCION M, CALVO RM, SAN MILLAN JL et al.:A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. I Clin. Endocrine] Metab.(2000) 85(7):2434–2438.
   Google Scholar
• AZZIZ R, WOODS KS, REYNA R et al.:The prevalence and features of the polycystic ovary syndrome in an unselected population. I Clin. Endocrine] Metab.(2004) 89(6):2745–2749.
   PubMed Web of Science ®Google Scholar
• •Largest prevalence study of PCOS in unselected women.
   Google Scholar
• ZAWADZKI JK, DUNAIF A: Diagnostic criteria for polycystic ovary syndrome. In: Polycystic Ovary Syndrome.AGJ Dunaif, F Haseltine, GR Merriam (Eds), Blackwell Scientific Publications, Boston, MA, USA (1992):377–384.
   Google Scholar
• ROTTERDAM ESHRE/ASRM-SPONSORED PCOS CONSENSUS WORKSHOP GROUP: Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fern] Steril.(2004) 81(1):19–25.
   Web of Science ®Google Scholar
• ••Current recommendations for thedefinition and management of PCOS.
   Google Scholar
• ROTTERDAM ESHRE/ASRM-SPONSORED PCOS CONSENSUS WORKSHOP GROUP: Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum. Reprod.(2004) 19(1):41–47.
   PubMed Web of Science ®Google Scholar
• ••Current recommendations for thedefinition and management of PCOS.
   Google Scholar
• STEIN IF, LEVENTHAL ML: Amenorrhea associated with bilateral polycystic ovaries. Am. Obstet. Cynecol(1935) 29:181–191.
   Google Scholar
• OVALLE F, AZZIZ R: Insulin resistance, polycystic ovary syndrome and Type 2 diabetes mellitus. Fern] Stern.(2002) 77(6):1095–1105.
   PubMed Web of Science ®Google Scholar
• LEGRO RS: Polycystic ovary syndrome and cardiovascular disease: a premature association? Ender]: Rev(2003) 24(3):302–312.
   PubMed Web of Science ®Google Scholar
• HARDIMAN P, PILLAY OS, ATIOMO W: Polycystic ovary syndrome and endometrial carcinoma. Lancet(2003) 361(9371):1810–1812.
   PubMed Web of Science ®Google Scholar
• WILLIAMSON K, GUNN AJ, JOHNSON N, MILSOM SR: The impact of ethnicity on the presentation of polycystic ovarian syndrome. Aust. NZ Obstet. Cynaecol(2001) 41(2):202–206.
   PubMed Web of Science ®Google Scholar
• CARMINA E, KOYAMA T, CHANG L, STANCZYK FZ, LOBO RA: Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in polycystic ovary syndrome? Am. Obstet. Cynecol(1992) 167(6):1807–1812.
   Web of Science ®Google Scholar
• FERRIMAN D, GALLWEY JD: Clinical assessment of body hair growth in women. Clin. Endocrine] Metab.(1961) 21:1440–1447.
   PubMed Web of Science ®Google Scholar
• HATCH R, ROSENFIELD RL, KIM MH, TREDWAY D: Hirsutism: implications, etiology and management. Am. Obstet. Cynecol(1981) 140(7):815–830.
   PubMed Web of Science ®Google Scholar
• CEREL-SUHL SL, YEAGER BF: Update on oral contraceptive pills. Am. Fam. Physician(1999) 60 (7) :2073-2084. Expert Op/n. lnvestig. Drugs (2004) 13(10)1301
   Google Scholar
• RAUDRANT D, RABE T: Progestogens with antiandrogenic properties. Drugs(2003) 63(5):463–492.
   PubMed Web of Science ®Google Scholar
• BURKMAN RT Jr: The role of oral contraceptives in the treatment of hyperandrogenic disorders. Am. J. Med.(1995) 98(1A):130S–136S.
   Google Scholar
• MASTORAKOS G, KOLIOPOULOS C, CREATSAS G: Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives. Fertil. Sterd.(2002) 77(5):919–927.
   PubMed Web of Science ®Google Scholar
• FALSETTI L, GAMBERA A, TISI G: Efficacy of the combination ethinyl oestradiol and cyproterone acetate on endocrine, clinical and ultrasonographic profile in polycystic ovarian syndrome. Hum. Reprod.(2001) 16(1):36–42.
   PubMed Web of Science ®Google Scholar
• OELKERS W: Drospirenone, a progestogen with antimineralocorticoid properties: a short review. MM. Cell. Endocrinol(2004) 217(1-2):255–261.
   PubMed Web of Science ®Google Scholar
• GUIDO M, ROMUALDI D, GIULIANI M et al:Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study. Clin. Endocrinol Metab.(2004) 89(6):2817–2823.
   Google Scholar
• AZZIZ R, OCHOA TM, BRADLEY EL Jr, POTTER HD, BOOTS LR: Leuprolide and estrogen versus oral contraceptive pills for the treatment of hirsutism: a prospective randomized study. j. Clin. Endocrinol Metab.(1995) 80(12):3406–3411.
   PubMed Web of Science ®Google Scholar
• CARMINA E, LOBO RA: Gonadotrophin-releasing hormone agonist therapy for hirsutism is as effective as high dose cyproterone acetate but results in a longer remission. Hum. Reprod.(1997) 12(0663–666.
   PubMed Web of Science ®Google Scholar
• CARMINA E: Anti-androgens for the treatment of hirsutism. Expert Opin.Investig. Drugs (2002) 11(3):357–363.
   PubMed Web of Science ®Google Scholar
• MARKUSSIS V, GONI MH, TOLIS G: Therapeutic use of gonadotropin-releasing hormone agonists in polycystic ovarian syndrome. Ann. NY Acad. Sci.(1993) 687:242–249.
   PubMed Web of Science ®Google Scholar
• RITTMASTER RS, LORIAUX DL, CUTLER GB Jr: Sensitivity of cortisol and adrenal androgens to dexamethasone suppression in hirsute women. I Clin. Endocrinol Metab.(1985) 61(3):462–466.
   PubMed Web of Science ®Google Scholar
• SAHIN Y, KELESTIMUR F: Medical treatment regimens of hirsutism. Reprod. Biomed. Online(2004) 8(5):538–546.
   PubMed Web of Science ®Google Scholar
• DIAMANTI-KANDARAKIS E: Current aspects of antiandrogen therapy in women. Carr. Pharm. Des.(1999) 5(9):707–723.
   PubMed Web of Science ®Google Scholar
• MOGHETTI P, TOSI F, TOSTI A et al.:Comparison of spironolactone, flutamide and finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial. I. Clin. Endocrinol Metab.(2000) 85(1):89–94.
   PubMed Web of Science ®Google Scholar
• •A well-designed study evaluating the effects of commonly used anti-androgens in hirsutism.
   Google Scholar
• SHAPIRO G, EVRON S: A novel use of spironolactone: treatment of hirsutism. Clin. Endocrinol Metab. (1980) 51(3):429–432.
   Google Scholar
• BARTH JH, CHERRY CA, WOJNAROWSKA F, DAWBER RP: Spironolactone is an effective and well tolerated systemic antiandrogen therapy for Hirsute women. J. Clin. Endocrinol Metab.(1989) 68(5):966–970.
   PubMed Web of Science ®Google Scholar
• SERAFINI P, LOBO RA: The effects of spironolactone on adrenal steroidogenesis in hirsute women. Fertil. Sterd.(1985) 44(5):595–599.
   PubMed Web of Science ®Google Scholar
• HELFER EL, MILLER JL, ROSE LI: Side-effects of spironolactone therapy in the hirsute woman. Clin. Endocrinol Metab.(1988) 66(1):208–211.
   Google Scholar
• BELISLE S, LOVE EJ: Clinical efficacy and safety of cyproterone acetate in severe hirsutism: results of a multicentered Canadian study. Fertil. Steil].(1986) 46(6):1015–1020.
   PubMed Web of Science ®Google Scholar
• MILLER JA, WOJNAROWSKA FT, DOWD PM et al:Anti-androgen treatment in women with acne: a controlled trial. Br: J. Dermatol(1986) 114(6):705–716.
   PubMed Web of Science ®Google Scholar
• MOWSZOWICZ I, WRIGHT F, VINCENS M et al.:Androgen metabolism in hirsute patients treated with cyproterone acetate. J. Steroid Biochem.(1984) 20(3):757–761.
   PubMedGoogle Scholar
• CUSAN L, DUPONT A, GOMEZ JL, TREMBLAY RR, LABRIE F: Comparison of flutamide and spironolactone in the treatment of hirsutism: a randomized controlled trial. Fertil. Steril.(1994) 61(2):281–287.
   PubMed Web of Science ®Google Scholar
• ERENUS M, GURBUZ 0, DURMUSOGLU F, DEMIRCAY Z, PEKIN S: Comparison of the efficacy of spironolactone versus flutamide in the treatment of hirsutism. Feral. Sterd.(1994) 61(4):613–616.
   PubMed Web of Science ®Google Scholar
• VENTUROLI S, MARESCALCHI 0, COLOMBO FM et al.:A prospective randomized trial comparing low dose flutamide, finasteride, ketoconazole and cyproterone acetate-estrogen regimens in the treatment of hirsutism. I Clin. Endocrinol Metab.(1999) 84(4):1304–1310.
   Google Scholar
• AZZIZ R, WAGGONER WT, OCHOA T, KNOCHENHAUER ES, BOOTS LR: Idiopathic hirsutism: an uncommon cause of hirsutism in Alabama. Fertil. (1998) 70(2):274–278.
   PubMed Web of Science ®Google Scholar
• FRANKS S: Polycystic ovary syndrome. N Engl. J. Med.(1995) 333(13):853–861.
   PubMed Web of Science ®Google Scholar
• PASQUALI R, CASIMIRRI F, VENTUROLI S etal.: Body fat distribution has weight-independent effects on clinical, hormonal and metabolic features of women with polycystic ovary syndrome. Metabolism(1994) 43(6):706–713.
   Google Scholar
• CLARK AM, LEDGER W, GALLETLY C et al.:Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women. Hum. Reprod.(1995) 10(10):2705–2712.
   PubMed Web of Science ®Google Scholar
• CLARK AM, THORNLEY B, TOMLINSON L, GALLETLEY C, NORMAN RJ: Weight loss in obese infertile women results in improvement in reproductive outcome for all forms of fertility treatment. Hum. Reprod.(1998) 13(6):1502–1505.
   PubMed Web of Science ®Google Scholar
• YILDIZ BO, CHANG W, AZZIZ R: Polycystic ovary syndrome and ovulation induction. Minerva Cinecol(2003) 55(5):425–439.
   PubMedGoogle Scholar
• CLARK JH, MARKAVERICH BM: The agonistic and antagonistic effects of short acting estrogens: a review. Pharmacol The]:(1983) 21(3):429–453.
   PubMed Web of Science ®Google Scholar
• THOMPSON CR, HANSEN LM: Pergonal (menotropins): a summary of clinical experience in the induction of ovulation and pregnancy. Fertil. Stern.(1970) 21(12):844–853.
   PubMed Web of Science ®Google Scholar
• WANG CF, GEMZELL C: The use of human gonadotropins for the induction of ovulation in women with polycystic ovarian disease. Feral. Sterd.(1980) 33(5):479–486.
   PubMed Web of Science ®Google Scholar
• HOMBURG R, HOWLES CM: Low-dose FSH therapy for anovulatory infertility associated with polycystic ovary syndrome: rationale, results, reflections and refinements. Hum. Reprod. Update(1999) 5(5)493–499.
   Google Scholar
• DUNAIF A: Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocc Rev (1997) 18(6):774–800.
   PubMed Web of Science ®Google Scholar
• •An excellent paper reviewing insulin action abnormalities and their role in the pathophysiology of PCOS.
   Google Scholar
• DUNAIF A, SEGAL KR, SHELLEY DR et al.:Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes(1992) 41(10):1257–1266.
   PubMed Web of Science ®Google Scholar
• CIARALDI TP, EL-ROEIY A, MADAR Z et al.:Cellular mechanisms of insulin resistance in polycystic ovarian syndrome. Clin. Endocrinol Metab.(1992) 75(2):577–583.
   Google Scholar
• DUNAIF A, XIA J, BOOK CB, SCHENKER E, TANG Z: Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome.," Clin. Invest.(1995) 96(2):801–810.
   Google Scholar
• BARBIERI RL, MAKRIS A, RYAN KJ: Insulin stimulates androgen accumulation in incubations of human ovarian stroma and theca. Obstet. Cynecol(1984) 64(3 Suppl.):73S–80S.
   Google Scholar
• WILLIS D, FRANKS S: Insulin action in human granulosa cells from normal and polycystic ovaries is mediated by the insulin receptor and not the type-I insulin-like growth factor receptor. I Clin. Endocrinol Metab.(1995) 80(12):3788–3790.
   PubMed Web of Science ®Google Scholar
• NESTLER JE, POWERS LP, MATT DW et al:A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. j. Clin. Endocrinol Metab.(1991) 72(1):83–89.
   PubMed Web of Science ®Google Scholar
• BEN-SHLOMO I, HOMBURG R, SHALEV E: Hyperandrogenic anovulation (the polycystic ovary syndrome)-back to the ovary? Hum. Reprod. Update(1998) 4(3)296–300.
   Google Scholar
• YILDIZ BO, GEDIK 0: Assessment of glucose intolerance and insulin sensitivity in polycystic ovary syndrome. Reprod. Biomed. Online(2004) 8(6):649–656.
   PubMed Web of Science ®Google Scholar
• DUNAIF A, SE GAL KR, FUTTERWEIT W, DOBRJANSKY A: Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes(1989) 38(9):1165–1174.
   PubMed Web of Science ®Google Scholar
• LEGRO RS, FINEGOOD D, DUNAIF A: A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J. Clin. Endocrinol Metab.(1998) 83(8):2694–2698.
   PubMed Web of Science ®Google Scholar
• KIRPICHNIKOV D, MCFARLANE SI, SOWERS JR: Metformin: an update. Ann. Intern. Med.(2002) 137(1):25–33.
   PubMed Web of Science ®Google Scholar
• VELAZQUEZ EM, MENDOZA S, HAMER T, SOSA F, GLUECK CJ: Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism(1994) 43(5):647–654.
   PubMed Web of Science ®Google Scholar
• NESTLER JE, JAKUBOWICZ DJ: Decreases in ovarian cytochrome P450c17a activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl. I Med.(1996) 335(9):617–623.
   PubMed Web of Science ®Google Scholar
• LORD J, FLIGHT I, NORMAN R: Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst. Rev(2003) 3:CD003053.
   Google Scholar
• ••Single, currently available meta-analysis assessing the role of insulin-sensitising agents for the treatment of PCOS.
   Google Scholar
• NESTLERJE, STOVALL D, AKHTER N, IUORNO MJ, JAKUBOWICZ DJ: Strategies for the use of insulin-sensitizing drugs to treat infertility in women with polycystic ovary syndrome. Fertil. Steril(2002) 77(2):209–215.
   PubMed Web of Science ®Google Scholar
• YARALI H, YILDIZ BO, DEMIROL A et al.:Co-administration of metformin during rFSH treatment in patients with clomiphene citrate-resistant polycystic ovarian syndrome: a prospective randomized trial. Hum. Reprod.(2002) 17(2):289–294.
   PubMed Web of Science ®Google Scholar
• KJOTROD SB, VON DURING V, CARLSEN SM: Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study. Hum. Reprod.(2004) 19(6):1315–1322.
   PubMed Web of Science ®Google Scholar
• HARBORNE L, FLEMING R, LYALL H, SATTAR N, NORMAN J: Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. J. Clin. Endocrinol Metab.(2003) 88(9):4116–4123.
   PubMed Web of Science ®Google Scholar
• IBANEZ L, FERRER A, ONG K et al:Insulin sensitization early after menarche prevents progression from precocious pubarche to polycystic ovary syndrome. Pediatr.(2004) 144(1):23–29.
   Web of Science ®Google Scholar
• GLUECK CJ, WANG P, KOBAYASHI S, PHILLIPS H, SIEVE-SMITH L: Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome. Fertil. Steril(2002) 77(3):520–525.
   PubMed Web of Science ®Google Scholar
• GLUECK CJ, AWADALLA SG, PHILLIPS H et al:Polycystic ovary syndrome, infertility, familial thrombophilia, familial hypofibrinolysis, recurrent loss of M vitrofertilized embryos and miscarriage. Feral. Steril.(2000) 74(2)394–397.
   Google Scholar
• BERGER J, MOLLER DE: The mechanisms of action of PPARs. Ann. Rev Med.(2002) 53:409–435.
   PubMed Web of Science ®Google Scholar
• DUNAIF A, SCOTT D, FINEGOOD D, QUINTANA B, WHITCOMB R: The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. I Gin. Endocrinol Metab.(1996) 81(9):3299–3306.
   PubMed Web of Science ®Google Scholar
• EHRMANN DA, SCHNEIDER DJ, SOBEL BE et al:Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis and fibrinolysis in women with polycystic ovary syndrome. Gin. Endocrinol Metab.(1997) 82(7):2108–2116.
   PubMed Web of Science ®Google Scholar
• AZZIZ R, EHRMANN D, LEGRO RS et al.:Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. I Clin. Endocrinol Metab.(2001) 86(4):1626–1632.
   PubMed Web of Science ®Google Scholar
• ••A well-designed study with the largestnumber of participants evaluating an insulin-sensitising agent in the management of PCOS.
   Google Scholar
• LEGRO RS, AZZIZ R, EHRMANN D et al.:Minimal response of circulating lipids in women with polycystic ovary syndrome to improvement in insulin sensitivity with troglitazone. I Clin. Endocrinol Metab.(2003) 88(11):5137–5144.
   PubMed Web of Science ®Google Scholar
• SCHEEN AJ: Thiazolidinediones and liver toxicity. Diabetes Metab.(2001) 27(3):305–313.
   PubMed Web of Science ®Google Scholar
• ••
   Google Scholar
• LEBOVITZ HE: Differentiating members of the thiazolidinedione class: a focus on safety. Diabetes Metab. Res. Rev(2002) 18\(Suppl. 2):S23–S29.
   Google Scholar
• CATALDO NA, ABBASI F, MCLAUGHLIN TL, LAMENDOLA C, REAVEN GM: Improvement in insulin sensitivity followed by ovulation and pregnancy in a woman with polycystic ovary syndrome who was treated with rosiglitazone. Fertil. Steril(2001) 76(5):1057–1059.
   PubMed Web of Science ®Google Scholar
• BELLI SH, GRAFFIGNA MN, ONETO A et al.:Effect of rosiglitazone on insulin resistance, growth factors and reproductive disturbances in women with polycystic ovary syndrome. Feral Steril(2004) 81(3):624–629.
   PubMed Web of Science ®Google Scholar
• GHAZEERI G, KUTTEH WH, BRYER-ASH M, HAAS D, KE RW: Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome. Feral Sterd.(2003) 79(3):562–566.
   PubMed Web of Science ®Google Scholar
• SHOBOKSHI A, SHAARAWY M: Correction of insulin resistance and hyperandrogenism in polycystic ovary syndrome by combined rosiglitazone and clomiphene citrate therapy. I Soc. Cynecol Investig.(2003) 10(2):99–104.
   PubMed Web of Science ®Google Scholar
• ROMUALDI D, GUIDO M, CIAMPELLI M et al.:Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome. Hum. Reprod.(2003) 18(6):1210–1218.
   PubMed Web of Science ®Google Scholar
• GUIDO M, ROMUALDI D, SURIANO R et al.:Effect of pioglitazone treatment on the adrenal androgen response to corticotrophin in obese patients with polycystic ovary syndrome. Hum. Reprod.(2004) 19(3):534–539.
   PubMed Web of Science ®Google Scholar
• GLUECK CJ, MOREIRA A, GOLDENBERG N, SIEVE L, WANG P: Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin. Hum. Reprod.(2003) 18(8):1618–1625.
   PubMed Web of Science ®Google Scholar
• COFFLER MS, PATEL K, DAHAN MH et al.:Enhanced granulosa cell responsiveness to follicle-stimulating hormone during insulin infusion in women with polycystic ovary syndrome treated with pioglitazone. Clio. Endocrinol Metab.(2003) 88(12):5624–5631.
   PubMed Web of Science ®Google Scholar
• BRETTENTHALER N, DE GEYTER C, HUBER PR, KELLER U: Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism and ovulatory dysfunction in women with polycystic ovary syndrome. I Clio. Endocrinol Metab.(2004) 89(8):3835–3840.
   PubMed Web of Science ®Google Scholar
• STUMVOLL M: Thiazolidinediones - some recent developments. Expert Opin. Investig. Drugs(2003) 12(7):1179–1187.
   PubMed Web of Science ®Google Scholar
• LARNER J: D-chiro-inositol in insulin action and insulin resistance-old-fashioned biochemistry still at work. IUBMB Life(2001) 51(3):139–148.
   PubMed Web of Science ®Google Scholar
• NESTLERJE, JAKUBOWICZ DJ, REAMER P, GUNN RD, ALLAN G: Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N. Engl. J. Med.(1999) 340(17):1314–1320.
   PubMed Web of Science ®Google Scholar
• EHRMANN DA, BARNES RB, ROSENFIELD RL, CAVAGHAN MK, IMPERIAL J: Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care(1999) 22(1):141–146.
   PubMed Web of Science ®Google Scholar
• LEGRO RS, KUNSELMAN AR, DODSON WC, DUNAIF A: Prevalence and predictors of risk for Type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. I Clio. Endocrinol Metab.(1999) 84(1):165–169.
   PubMed Web of Science ®Google Scholar
• WEERAKIET S, SRISOMBUT C, BUNNAG P et al:Prevalence of Type 2 diabetes mellitus and impaired glucose tolerance in Asian women with polycystic ovary syndrome. hat. J. Cynaecol Obstet.(2001) 75(2):177–184.
   Web of Science ®Google Scholar
• NORMAN RJ, MASTERS L, MILNER CR, WANG JX, DAVIES MJ: Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome. Hum. Reprod.(2001) 16 (9) :1995–1998.
   PubMed Web of Science ®Google Scholar
• AMERICAN DIABETES ASSOCIATION: Screening for diabetes. Diabetes Care(2002) 25 (1) :21–24.
   Google Scholar
• KNOWLER WC, BARRETT-CONNOR E, FOWLER SE et al.:Reduction in the incidence of Type 2 diabetes with lifestyle intervention or metformin. N Engl. I Med.(2002) 346(6):393–403.
   PubMed Web of Science ®Google Scholar
• ••A well-designed, multi-centre studydemonstrating the role of lifestyle modification and metformin in the prevention of diabetes.
   Google Scholar
• TUOMILEHTO J, LINDSTROM J, ERIKSSON JG et al.:Prevention of Type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl. J. Med.(2001) 344(18):1343–1350.
   PubMed Web of Science ®Google Scholar
• BRAY GA: Medical consequences of obesity. J. Clio. Endocrinol Metab.(2004) 89(6):2583–2589.
   PubMed Web of Science ®Google Scholar
• KIDDY DS, HAMILTON-FAIRLEY D, BUSH A et al.:Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clio. Endocrinol(1992) 36(1):105–111.
   PubMed Web of Science ®Google Scholar
• MORAN LJ, NOAKES M, CLIFTON PM, TOMLINSON L, NORMAN RJ: Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome. J. Clio. Endocrinol Metab.(2003) 88(2):812–819.
   PubMed Web of Science ®Google Scholar
• PASQUALI R, ANTENUCCI D, CASIMIRRI F et al.:Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss. Clio. Endocrinol Metab.(1989) 68 (1) :173–179.
   PubMed Web of Science ®Google Scholar
• GUZICK DS, WING R, SMITH D, BERGA SL, WINTERS SJ: Endocrine consequences of weight loss in obese, hyperandrogenic, anovulatory women. Feral Steril.(1994) 61(4):598–604.
   PubMed Web of Science ®Google Scholar
• HUBER-BUCHHOLZ MM, CAREY DG, NORMAN RJ: Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. J. Clio. Endocrinol Metab.(1999) 84(4):1470–1474.
   PubMed Web of Science ®Google Scholar
• CHANG RJ, NAKAMURA RM, JUDD HL, KAPLAN SA: Insulin resistance in nonobese patients with polycystic ovarian disease. Clio. Endocrinol Metab.(1983) 57(2):356–359.
   PubMed Web of Science ®Google Scholar
• CONWAY GS, AGRAWAL R, BETTERIDGE DJ, JACOBS HS: Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome. Clio. Endocrinol(1992) 37(2):119–125.
   PubMed Web of Science ®Google Scholar
• YILDIZ BO, HAZNEDAROGLU IC, KIRAZLI S, BAYRAKTAR M: Global fibrinolytic capacity is decreased in polycystic ovary syndrome, suggesting a prothrombotic state. I Clio. Endocrinol Metab.(2002) 87(8):3871–3875.
   PubMed Web of Science ®Google Scholar
• MATHER KJ, KWAN F, CORENBLUM B: Hyperinsulinemia in polycystic ovary syndrome correlates with increased cardiovascular risk independent of obesity. Fertil. Stern.(2000) 73 ( 1) : 150–156.
   PubMed Web of Science ®Google Scholar
• KIRCHENGAST S, HUBER J: Body composition characteristics and body fat distribution in lean women with polycystic ovary syndrome. Hum. Reprod.(2001) 16(6):1255–1260.
   PubMed Web of Science ®Google Scholar
• YILDIRIM B, SABIR N, KALELI B: Relation of intra-abdominal fat distribution to metabolic disorders in nonobese patients with polycystic ovary syndrome. Fertil. Steril(2003) 79 (6) :1358–1364.
   PubMed Web of Science ®Google Scholar